Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases

Knopp Biosciences LLC announced it received U.S. Patent No. 9,468,630 entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils”.  The patent relates to the company’s clinical-stage small molecule dexpramipexole, which Knopp expects to advance into pivotal trials in HES and Phase 2 trials in eosinophilic asthma in 2017. Read more…

 

×

Comments are closed.